The regenerative medicine sector that embraces gene and cell therapies continues to expand, particularly on the business and clinical development fronts. For example, a panel at the Neurosciences 2018 conference discussed just how rapidly the science is evolving and now beginning to take on harder-to-treat diseases, with gene therapies already in early stage development targeting amyotrophic lateral sclerosis, Parkinson's disease and Batten disease. Read More
Now that the votes are in, the midterm election gives the U.S. a House/Senate outcome that will likely maintain the political status quo. It is predicted that for the next two years at least, with the Democrats controlling the House of Representatives and the Republicans in control of the Senate, implementation of new policies will be a challenge in Washington. (See BioWorld, Nov. 8, 2018.) Read More
